FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980392701> ?p ?o ?g. }

• W2980392701 endingPage "A1169" @default.
• W2980392701 startingPage "A1169" @default.
• W2980392701 abstract "SESSION TITLE: Tuesday Electronic Posters 4 SESSION TYPE: Original Inv Poster Discussion PRESENTED ON: 10/22/2019 01:00 PM - 02:00 PM PURPOSE: Inhalers should be easy to operate correctly to ensure effective delivery of inhaled medications. Since an inadequate technique has the potential to reduce the effects of medication, the development of an easy-to-use inhaler that delivers the drug to the lungs effectively is important. The ELLIPTA inhaler is a dry powder inhaler that has been developed for the delivery of a range of inhaled medications. Because of the known problems with incorrect technique with some inhalers, it is important to demonstrate that patients can correctly use the ELLIPTA inhaler and find it easy to use. METHODS: This meta-analysis study was designed to assess the proportion of subjects with COPD who demonstrate correct use of the ELLIPTA inhaler (ELLIPTA is a trade mark owned by or licensed to the GSK group of companies) and to determine the proportion of subjects who rate the use of the ELLIPTA inhaler as easy or very easy to use at the end of the study. The meta-analysis inclusion criteria were open-label placebo ELLIPTA inhaler studies in patients with COPD with a reported outcome of correct use and/or ease of use. Non-placebo studies, reviews and conference abstracts were excluded. The Intent-to-Treat Population was used for all study population and safety analyses. There are no treatment comparisons in this meta-analysis. Four studies met the criteria for inclusion into this meta-analysis: GSK study 200301/NCT02184624; GSK study 201701/NCT02586493; GSK study 206215/NCT02982187 and GSK206901/NCT03227445. RESULTS: 1232 COPD patients were included: median age 66.2 years, 43% female. At study end, 80.1% demonstrated correct inhaler use. Analysis of correct use by age groups of 40-64 (n=478 correct use 85.1%); 65-74 (n=550; correct use of 77.6%) and ≥75 years old (n=189; correct use of 74.6%) indicated consistent correct use with increasing age of patients. Of the 4 studies, 2 assessed ease of use (n=833). 95.7% rated the inhaler as ‘easy’ or ’very easy’ to use with very little difference by age groups. AE rates were 6%; the most frequent AE was headache (<1%). Seven patients reported eight treatment-related AEs (cough, n=4; dyspnea, n=1; oral paresthesia, n=1; laceration, n=1; back pain, n=1). CONCLUSIONS: The ELLIPTA inhaler was operated correctly and rated ‘easy’ or ‘very easy’ to use by the majority of COPD patients irrespective of age group. CLINICAL IMPLICATIONS: The clinical implications of this meta-analysis is a successful demonstration of correct use of the ELLIPTA device by a majority of COPD patients enrolled in these trials. It was also rated as easy or very easy to use in a subset of these trials. When the correct use data was analyzed across age groups, there was consistent correct use by all age groups. DISCLOSURES: Employee relationship with GSK Please note: >$100000 Added 01/29/2019 by Lee Baylis, source=Web Response, value=Salary Employee relationship with GlaxoSmithKline Please note: >$100000 Added 01/30/2019 by Kathryn Collison, source=Web Response, value=Salary Employee relationship with GlaxoSMithKline Please note: $20001 - $100000 Added 01/30/2019 by Kathryn Collison, source=Web Response, value=Shares Employee relationship with GSK Please note: >$100000 Added 01/29/2019 by Renu Jain, source=Web Response, value=Salary No relevant relationships by Pinal Patel, source=Web Response Employee relationship with Glaxosmithkline Please note: $20001 - $100000 Added 02/07/2019 by raj sharma, source=Web Response, value=Salary Employee relationship with GlaxoSmithKline Please note: >$100000 Added 01/29/2019 by Laura Sutton, source=Web Response, value=Salary" @default.
• W2980392701 created "2019-10-25" @default.
• W2980392701 creator A5004313879 @default.
• W2980392701 creator A5024567683 @default.
• W2980392701 creator A5029632697 @default.
• W2980392701 creator A5044084700 @default.
• W2980392701 creator A5050171498 @default.
• W2980392701 creator A5075758556 @default.
• W2980392701 date "2019-10-01" @default.
• W2980392701 modified "2023-10-16" @default.
• W2980392701 title "A META-ANALYSIS OF THE EASE OF USE AND CORRECT USE OF PLACEBO ELLIPTA DRY POWDER INHALER IN SUBJECTS WITH COPD" @default.
• W2980392701 doi "https://doi.org/10.1016/j.chest.2019.08.1064" @default.
• W2980392701 hasPublicationYear "2019" @default.
• W2980392701 type Work @default.
• W2980392701 sameAs 2980392701 @default.
• W2980392701 citedByCount "0" @default.
• W2980392701 crossrefType "journal-article" @default.
• W2980392701 hasAuthorship W2980392701A5004313879 @default.
• W2980392701 hasAuthorship W2980392701A5024567683 @default.
• W2980392701 hasAuthorship W2980392701A5029632697 @default.
• W2980392701 hasAuthorship W2980392701A5044084700 @default.
• W2980392701 hasAuthorship W2980392701A5050171498 @default.
• W2980392701 hasAuthorship W2980392701A5075758556 @default.
• W2980392701 hasConcept C126322002 @default.
• W2980392701 hasConcept C142724271 @default.
• W2980392701 hasConcept C177713679 @default.
• W2980392701 hasConcept C1862650 @default.
• W2980392701 hasConcept C204787440 @default.
• W2980392701 hasConcept C27081682 @default.
• W2980392701 hasConcept C2776042228 @default.
• W2980392701 hasConcept C2776780178 @default.
• W2980392701 hasConcept C2777419714 @default.
• W2980392701 hasConcept C2780261241 @default.
• W2980392701 hasConcept C2908647359 @default.
• W2980392701 hasConcept C71924100 @default.
• W2980392701 hasConcept C95190672 @default.
• W2980392701 hasConcept C99454951 @default.
• W2980392701 hasConceptScore W2980392701C126322002 @default.
• W2980392701 hasConceptScore W2980392701C142724271 @default.
• W2980392701 hasConceptScore W2980392701C177713679 @default.
• W2980392701 hasConceptScore W2980392701C1862650 @default.
• W2980392701 hasConceptScore W2980392701C204787440 @default.
• W2980392701 hasConceptScore W2980392701C27081682 @default.
• W2980392701 hasConceptScore W2980392701C2776042228 @default.
• W2980392701 hasConceptScore W2980392701C2776780178 @default.
• W2980392701 hasConceptScore W2980392701C2777419714 @default.
• W2980392701 hasConceptScore W2980392701C2780261241 @default.
• W2980392701 hasConceptScore W2980392701C2908647359 @default.
• W2980392701 hasConceptScore W2980392701C71924100 @default.
• W2980392701 hasConceptScore W2980392701C95190672 @default.
• W2980392701 hasConceptScore W2980392701C99454951 @default.
• W2980392701 hasIssue "4" @default.
• W2980392701 hasLocation W29803927011 @default.
• W2980392701 hasOpenAccess W2980392701 @default.
• W2980392701 hasPrimaryLocation W29803927011 @default.
• W2980392701 hasRelatedWork W1985297785 @default.
• W2980392701 hasRelatedWork W2109586110 @default.
• W2980392701 hasRelatedWork W2153441442 @default.
• W2980392701 hasRelatedWork W2790147388 @default.
• W2980392701 hasRelatedWork W2904406609 @default.
• W2980392701 hasRelatedWork W2906043870 @default.
• W2980392701 hasRelatedWork W4288721600 @default.
• W2980392701 hasRelatedWork W4315780469 @default.
• W2980392701 hasRelatedWork W2473810395 @default.
• W2980392701 hasRelatedWork W3087902455 @default.
• W2980392701 hasVolume "156" @default.
• W2980392701 isParatext "false" @default.
• W2980392701 isRetracted "false" @default.
• W2980392701 magId "2980392701" @default.
• W2980392701 workType "article" @default.